Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia

Keyphrases

• Acute Myeloid Leukemia 71%
• Area Cover 14%
• Clinical Benefit 28%
• Combination Therapy 14%
• Complete Remission 14%
• Current Treatment 14%
• Daily Dose 14%
• Drug Profile 14%
• Duration of Response 14%
• Efficacy Data 14%
• Expert Opinion 14%
• IDH Inhibitors 100%
• IDH mutation 28%
• Isocitrate Dehydrogenase 1 (IDH1) 57%
• Monotherapy 28%
• New Treatment Options 14%
• Novel mutant 100%
• Olutasidenib 100%
• Overall Survival Rate 14%
• Phase II Trial 14%
• Recurrent mutation 14%
• Relapsed or Refractory 14%
• Relapsed or Refractory Acute Myeloid Leukemia 100%
• Remission 14%
• Safety Benefits 14%
• Safety Data 14%
• Safety Profile 14%
• Site-directed mutation 28%
• Targeted Agents 14%
• Therapeutic Landscapes 14%
• Treatment Options 28%
• Twice Daily 14%
• U.S. Food 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Acute Myeloid Leukemia 100%
• Combination Therapy 14%
• Isocitrate Dehydrogenase 1 57%
• Monotherapy 28%
• Overall Survival 14%
• Remission 28%
• Survival Rate 14%